Several trials are investigating PSMA-RPT in combination with other treatment modalities to improve cancer therapy, including chemotherapy (NCT05340374), immunotherapy [105], and targeted therapies (NCT03874884) [106]. This evidence concerns the gene FOLH1 and cancer.